Edwards Lifesciences
$85.19Change from previous close: −1.31%Absolute change: −$1.13
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $49.05B
- Enterprise value
- $45.66B
- P/E (trailing 12 months)
- 50.7
- Forward P/E
- 25.2
- PEG
- 1.84
- Price/book
- 4.63
- Price/sales
- 7.53
- EV/EBITDA
- 22.9
- EV/revenue
- 7.01
Profitability and growth
- Gross margin
- 77.8%
- Operating margin
- 29.8%
- Net margin
- 15.4%
- ROE
- 9.2%
- ROA
- 8.4%
- Revenue growth (year over year)
- 13.6%
- Earnings growth (year over year)
- -25.4%
Financial health
- Total cash
- $4.25B
- Total debt
- $704.4M
- Debt/equity
- 0.07
- Current ratio
- 4.52
- Quick ratio
- 3.45
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $100.96
- Median price target
- $101.50
- High price target
- $110.00
- Low price target
- $84.00
- Analysts with a price target
- 26
- Consensus
- Buy
- Forward EPS
- $3.38
- EPS estimate, current year
- $3.00
Shares and trading
- Beta
- 0.85
- Average volume
- 3.87M
- Shares outstanding
- 575.8M
- Float
- 574.49M
- Institutional ownership
- 95.6%
- Insider ownership
- 0.2%
- Short interest (% of float)
- 1.8%
- Short ratio (days)
- 3.20